Sanilabo · IMMUNOQUICK PRODUCTOS 2012 Article Number DIMA ... IMMUNOQUICK CONTACT MALARIA +4 ......

IMMUNOQUICKPRODUCTOS 2012

SanilaboSanitaria de laboratorio

C/San Roque nº30 Bajo46910 Benetusser - ValenciaT. +34 96 395 08 09 / 902 100 275 F. +34 96 374 04 84 / 902 100 274 T. +34 902 100 275T. +34 902 100 275

SANILABO S.L.Para cualquier sugerencia: [email protected]

Suministramos cualquier tipo de material, equipo o marca para su laboratorio

WebSite: www.sanilabo.comWebShop: www.sanilaboshop.es

VALENCIA

MURCIABALEARES






VALENCIA

MURCIABALEARES



Article Number

DIMA

Article Number

BIOSYNEX

IMMUNOQUICK NOROVIRUS

B-NORO-F23 0529_K10 ✓ Feces 10 tests/kit ✓

IMMUNOQUICK Adenovirus

B-ADEN-F23 0540_K25 ✓ Feces 25 tests/kit ✓

IMMUNOQUICK Rotavirus

B-ROTA-F23 0541_K25 ✓ Feces 25 tests/kit ✓

IMMUNOQUICK Adeno/Rota Combo

B-RAC-F23 0542_K25 ✓ Feces 25 tests/kit ✓

IMMUNOQUICK Filtration EBV lgM

B-EBVM-S23 0515_K25 ✓ Serum 25 tests/kit ✓

IMMUNOQUICK Filtration EBV MONO

B-EBV-S23 0539_K25 ✓ Serum 25 tests/kit ✓

IMMUNOQUICK Filtration EBV lgG

B-EBVG-S23 0516_K25 ✓ Serum 25 tests/kit ✓

IMMUNOQUICK Filtration HSV 1/2 lgG

B-HSV-S23S 0526_K12 ✓ Serum 12 tests/kit ✓

B-HSV-S23M 0526_K20 ✓ Serum 20 tests/kit ✓

IMMUNOQUICK RSV

B-RSV-S 23 0504_K10 ✓ Nasopharyngeal Swab 10 tests/kit ✓

IMMUNOQUICK Filtration VZV lgG

B-VZV-S23 0543_K25 ✓ Serum 25 tests/kit ✓

IMMUNOQUICK MONO

B-MONO-S11 0511_K50 ✓ Serum 50 tests/kit ✓

IMMUNOQUICK MALARIA Falciparum

B-MLPF-W11 0502_K25 ✓ Whole Blood 25 tests/kit ✓

Infectious Disease (ID)

cile GDH

B-GDH-F23 0537_K25 ✓ Feces 25 tests/kit ✓

Article Number DIMA

Article Number BIOSYNEX

IMMUNOQUICK MALARIA +4

B-MLPA-W11 0506_K25 ✓ Whole Blood 25 tests/kit ✓

IMMUNOQUICK CONTACT FALCIPARUM

B-MLPF-CW11 0519_K25 ✓ Whole Blood 25 tests/kit ✓

IMMUNOQUICK CONTACT MALARIA +4

B-MLPA-CW11 0525_K25 ✓ Whole Blood 25 tests/kit ✓

IMMUNOQUICK TETANUS

B-TET-W23 0514_K20 ✓ Whole Blood/Serum 20 tests/kit ✓

Autoimmunity DiseasesArticle Number DIMA

Article Number BIOSYNEX

IMMUNOQUICK Rheumatoid Factor

B-RHF-S11 0501_K50H ✓ Serum 50 tests/kit ✓

IMMUNOQUICK TG

B-THG-S11 0507_K10 ✓ Serum 10 tests/kit ✓

IMMUNOQUICK TPO

B-TPO-S11 0508_K10 ✓ Serum 10 tests/kit ✓

IMMUNOQUICK Filtration CELIAC IgA

B-CEL-S23 0518_K12 ✓ Serum 12 tests/kit ✓

Legend: Strip/Dipstick

Cassette Multi-Line Multi-Dip Specimen Packaging





VALENCIA

MURCIABALEARES







VALENCIA

MURCIABALEARES



CLINICAL AND V ACCINE I MMUNOLOGY , June 2009, p. 000 Vol. 16, No. 61556-6811/09/$08.00 0 doi:10.1128/CVI.00123-09

Evaluation of an Immunofiltration Assay That Detects Immunoglobulin MAntibodies against the ZEBRA Protein for the Diagnosis of Epstein-Barr

Virus Infectious Mononucleosis in Immunocompetent PatientsDayana Bravo, Beatriz Munoz-Cobo, Elisa Costa, M. Angeles Clari, Nuria Tormo, and David Navarro*

Department of Microbiology, Hospital Clínico Universitario, Valencia, Spain

Received 21 March 2009/Returned for modification 17 April 2009/Accepted 21 April 2009

The performance of an immunofiltration assay (IMFA) that detects immunoglobulin M (IgM) antibodies tothe Epstein-Barr virus (EBV) ZEBRA (BamHI Z EBV replication activator) protein was evaluated for thediagnosis of EBV infectious mononucleosis (IM) in immunocompetent patients. The test panel consisted of 47sera from patients with clinical and biological features of EBV IM and with an EBV-specific antibody profilecompatible with an acute primary EBV infection, 20 sera from healthy individuals with either a past EBVinfection or an EBV-seronegative history, 20 sera displaying an equivocal EBV-specific antibody pattern (viralcapsid antigen IgG positive [VCA IgG ], VCA IgM , and EBV nuclear antigen-1 IgG ), and 15 sera obtainedfrom patients with a mononucleosis-like syndrome owing to cytomegalovirus, human herpesvirus 6, or parvo-virus B19. Overall, the sensitivity and the specificity of the assay were found to be 92.5%, and 97.3%,respectively. The sensitivity of the assay for the diagnosis of heterophile antibody-negative EBV IM was 86.2%.The IMFA is rapid, easy to perform, and, thus, suitable for point-of-care testing, and it may be used as afirst-line test for the diagnosis of acute EBV IM in immunocompetent patients.

Diagnosis of Epstein-Barr virus (EBV) infectious mononu-cleosis (IM) is commonly made on the basis of characteristicclinical manifestations and the detection of heterophile anti-bodies (HA). Nevertheless, HA may be absent, particularly inyoung children (14) but also in as many as 20% of adults withEBV IM (7). In these cases, demonstration of the presence ofEBV viral capsid antigen (VCA) immunoglobulin G (IgG)and/or IgM antibodies, along with the absence of IgG antibod-ies to EBV nuclear antigen-1 (EBNA-1), allows the diagnosisof EBV primary infection (9). Detection of EBV-specific an-tibodies is accomplished by the use of commercial enzymeimmunoassays, indirect immunofluorescence assays, line blotimmunoassays (9), or, as established more recently, a multi-plexed bead assay (3). These methods have long turnaroundtimes, are labor-intensive, or require specific instruments orskilled technologists for their performance. In addition, inter-pretation of EBV VCA IgG/IgM and EBNA-1 IgG reactivityprofiles is not always straightforward (9).The ZEBRA (BamHI Z EBV replication activator) protein

is encoded by the immediate early BZLF1 gene. ZEBRA isexpressed during the lytic cycle in EBV-permissive cells andplays a critical role in transactivating several immediate early,early, and late EBV genes (5). Antibodies against ZEBRA areproduced during primary EBV infection (11, 15, 18), and thus,the detection of ZEBRA-specific IgMs may allow an earlydiagnosis of EBV IM. In the present study, we evaluated arapid and easy-to-perform immunofiltration assay (IMFA) de-tecting IgMs to the EBV ZEBRA protein for the biologicaldiagnosis of IM in immunocompetent patients.

MATERIALS AND METHODS

Serum specimens. A total of 102 sera submitted to our laboratory from 2005to 2008 for routine EBV-specific antibody testing for diagnostic purposes wereevaluated in this study. Serum samples were stored at 20°C immediately afterseparation and were retrieved for further analysis.

Immunoassays. VCA IgG, VCA IgM, and EBNA-1 IgG antibodies weredetected by enzyme immunoassays (EIAs) (Captia) from Trinity-Biotech (Bray,Ireland). VCA IgG avidity studies were performed following a previously pub-lished protocol (6, 8, 12). In brief, VCA IgG avidity was determined with theVCA IgG EIA (Captia), with the first wash step modified to include two washes(five minutes each) with a washing bu�er containing urea (8 M). The avidityindex value (as a percentage) was calculated as follows: (absorbance of VCAIgGs in the presence of urea/absorbance of VCA IgG in the absence of urea)100. IgG avidity index values less than 50% were considered compatible with arecent primary EBV infection (8). In our experience, sera from patients with aremote EBV infection (VCA IgG positive [VCA IgG ]/EBNA-1 IgG /VCAIgM /HA-positive) give VCA IgG avidity values greater than 75%, whereasthose for sera from patients with demonstrated recent primary EBV infection(VCA IgM /VCA IgG /EBNA-1 IgG /HA-positive) are less than 50% (datanot shown). HA were detected by a di�erential agglutination assay (I.M. kit;Microgen, Surrey, Great Britain). Parvovirus B19-specific IgG and IgMs weredetected by an EIA from Biotrin International (Dublin, Ireland). Cytomegalo-virus (CMV)-specific IgG and IgM antibodies were detected by the respectiveArchitect or Axsym CMV assay (Abbott Diagnostics, IL). IgG and IgM antibod-ies to human herpesvirus-6 (HHV-6) were detected by an EIA from Panbio(Queensland, Australia). For all EIAs, interpretation of the results was madeaccording to the instructions of the respective manufacturer.

IMFA. The IMFA (flowthrough device) is based on an assay principle in whichthe sample and a variety of reagent and wash solutions are sequentially absorbedthrough a porous membrane containing spots or lines o� mmobilized analyte-specific or control antibodies (reviewed in reference 17). The ImmunoquickFiltration EBV M assay (referred to as the IMFA herein) was performed fol-lowing the instructions of the manufacturer (BioSynex Immunodiagnostic, Stras-bourg Cedex, France). Briefly, a volume of 25 l of serum was diluted in 1.5 mlof dilution bu�er in a plastic tube. The diluted sample was then poured directlyfrom the tube into the device window and allowed to drain for 15 s. Theconjugate (1.5 ml) was then added and allowed to drain through the devicewindow (15 s). The washing bu�er (1.5 ml) was added next, and the reaction wasread as soon as the bu�er was fully drained through the device window. Theappearance of T1 (ZEBRA synthetic peptide) and control (immobilized proteinA) blue bands indicated the presence of ZEBRA-specific IgM antibodies. Theappearance of the control band in the absence of the T1 band indicated a

Sanilabo · IMMUNOQUICK PRODUCTOS 2012 Article Number DIMA ... IMMUNOQUICK CONTACT MALARIA +4 ......

Documents

Transcript of Sanilabo · IMMUNOQUICK PRODUCTOS 2012 Article Number DIMA ... IMMUNOQUICK CONTACT MALARIA +4 ......